IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study

Ionis announced it has completed enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions. The milestone reduces a key execution risk for the program and is a positive catalyst for near-term trial progress and future approval odds.

Analysis

Ionis announced it has completed enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions. The milestone reduces a key execution risk for the program and is a positive catalyst for near-term trial progress and future approval odds.